Imagen

Investigación sobre el melanoma

Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Blog - Melanoma360
, 
Noticias de última hora
, 
Investigación sobre el melanoma
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Blog - Melanoma360
, 
Investigación sobre el melanoma
Featured image for “A Letter From Our Vice President | January 2023”
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Blog - Melanoma360
, 
Investigación sobre el melanoma
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Blog - Melanoma360
, 
Investigación sobre el melanoma
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Blog - Melanoma360
, 
Investigación sobre el melanoma
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Blog - Melanoma360
, 
Noticias de última hora
, 
Investigación sobre el melanoma
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Blog - Melanoma360
, 
Noticias de última hora
, 
Investigación sobre el melanoma
Featured image for "Entrevista con la Dra. Zeynep Eroglu, oncóloga médica de Moffitt Cancer Center"
05/25/2022

Entrevista con la Dra. Zeynep Eroglu, oncóloga médica de Moffitt Cancer Center

La Dra. Zeynep Eroglu es oncóloga médica en Moffitt Cancer Center en Florida. Los intereses de investigación de la Dra. Eroglu son la traslación y la...
Blog - Melanoma360
, 
Investigación sobre el melanoma
Featured image for "Preguntas frecuentes y novedades sobre la AIM en el Consorcio Internacional de Bancos de Tejidos de Melanoma"
05/25/2022

Preguntas frecuentes y novedades sobre AIM en el Consorcio Internacional de Bancos de Tejidos de Melanoma

EL TEJIDO ES EL TEMA La principal iniciativa de investigación de AIM at Melanoma, el Consorcio Internacional de Bancos de Tejidos de Melanoma (IMTBC), es la primera de su...
Blog - Melanoma360
, 
Investigación sobre el melanoma
Featured image for "El COVID-19 ha creado una acumulación de cánceres sin diagnosticar, incluido el melanoma"
05/25/2022

La COVID-19 ha creado una acumulación de cánceres sin diagnosticar, incluido el melanoma

Por Erin Bekes En un estudio del Dr. Antoine Eskander y sus colegas descrito en el Journal of the National Comprehensive...
Blog - Melanoma360
, 
Investigación sobre el melanoma
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
Blog - Melanoma360
 | 
Noticias de última hora
 | 
Investigación sobre el melanoma
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
Blog - Melanoma360
 | 
Investigación sobre el melanoma
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Featured image for “A Letter From Our Vice President | January 2023”
Blog - Melanoma360
 | 
Investigación sobre el melanoma
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
Blog - Melanoma360
 | 
Investigación sobre el melanoma
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
Blog - Melanoma360
 | 
Investigación sobre el melanoma
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
Blog - Melanoma360
 | 
Noticias de última hora
 | 
Investigación sobre el melanoma
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
Blog - Melanoma360
 | 
Noticias de última hora
 | 
Investigación sobre el melanoma
05/25/2022

Entrevista con la Dra. Zeynep Eroglu, oncóloga médica de Moffitt Cancer Center

La Dra. Zeynep Eroglu es oncóloga médica en Moffitt Cancer Center en Florida. Los intereses de investigación de la Dra. Eroglu son la traslación y la...
Featured image for "Entrevista con la Dra. Zeynep Eroglu, oncóloga médica de Moffitt Cancer Center"
Blog - Melanoma360
 | 
Investigación sobre el melanoma
05/25/2022

Preguntas frecuentes y novedades sobre AIM en el Consorcio Internacional de Bancos de Tejidos de Melanoma

EL TEJIDO ES EL TEMA La principal iniciativa de investigación de AIM at Melanoma, el Consorcio Internacional de Bancos de Tejidos de Melanoma (IMTBC), es la primera de su...
Featured image for "Preguntas frecuentes y novedades sobre la AIM en el Consorcio Internacional de Bancos de Tejidos de Melanoma"
Blog - Melanoma360
 | 
Investigación sobre el melanoma
05/25/2022

La COVID-19 ha creado una acumulación de cánceres sin diagnosticar, incluido el melanoma

Por Erin Bekes En un estudio del Dr. Antoine Eskander y sus colegas descrito en el Journal of the National Comprehensive...
Featured image for "El COVID-19 ha creado una acumulación de cánceres sin diagnosticar, incluido el melanoma"
Blog - Melanoma360
 | 
Investigación sobre el melanoma

Entradas recientes

Featured image for “Transformation after Trauma”
Mar. 14, 2023

Transformation after Trauma

Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
Feb. 28, 2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

Featured image for “Functional Nutrition for Cancer Survivors”
Feb. 07, 2023

Functional Nutrition for Cancer Survivors

Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
Jan. 27, 2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

Featured image for “A Letter From Our Vice President | January 2023”
Jan. 26, 2023

A Letter From Our Vice President | January 2023

Filtrar por etiqueta